Precision Medicine
-
Neuro Biotech Alto Adds $128M in IPO Cash for Biomarker-Based Psych Drugs
Alto Neuroscience will apply the IPO proceeds toward clinical tests of its psychiatric drugs in patients who exhibit certain biomarkers. The company’s two most advanced programs are depression drugs in mid-stage development.
-
Personalized Medicine Is Revolutionizing the Role of Pharma Companies in the Healthcare Landscape
The more pharma companies do to become service providers in the personalized medicine era, the more they’ll succeed and the more lives they’ll help to save.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
How Artificial Intelligence Could Be the Ultimate Weapon Against Cancer
Cancer treatment is one area that could benefit significantly from AI, as it can aid in early detection, precise diagnosis, and personalized treatment plans.
-
MedCity Influencers, BioPharma, Health Tech
Key Trends from the 2024 J.P. Morgan Healthcare Conference
Key trends such as the resilience of the emerging biopharma space, the complexities of Medicare, and the revolutionary role of data and AI are shaping the future of the industry.
-
Goldman Sachs Closes $650M Fund to Invest in ‘Golden Era’ of Biotech Innovation
Goldman Sachs’s new fund—its first dedicated to life sciences—will focus on early- to mid-stage therapeutics companies with multiple assets. Genetic medicine, cell therapy, immunotherapy, and artificial intelligence are among the areas of investment interest for the firm.
-
MedCity Influencers, Devices & Diagnostics, Artificial Intelligence
AI Can Make Precision Medicine More Accessible to Patients Who Might Not Have Been Able to Benefit in the Past
“Precision medicine” is a term we have heard a lot over the last two decades, […]
-
Devices & Diagnostics, Artificial Intelligence
Season 2 of MedCity Pivot Podcast Launches with Conversation of Zephyr AI CTO
Season 2 of our MedCity Pivot Podcast launches today with a conversation about how AI can be leveraged to transform precision medicine.
-
Merck’s $11B Prometheus Acquisition Brings IBD Drug & Precision Medicine Platform
Merck is acquiring Prometheus Biosciences and a lead drug candidate in development for inflammatory bowel disorders. The deal comes as Merck looks for drug prospects that could make up for revenue declines facing blockbuster seller Keytruda, which faces patent expirations in coming years.
-
MedCity Influencers, BioPharma
Improving Value-based Care with Optimized Drug Therapy
Optimizing drug routines allows prescribers to make more informed decisions that reduce risk and improve quality of care. The result is better outcomes for both patients and organizations.
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
Nest Genomics Raises $8.5M to Increase Access to Patients’ Genetic Information
Nest Genomics just closed a $8.5 million seed financing round. The company provides the software infrastructure needed for health systems, clinics, drugmakers and payers to launch and scale genomic programs. It also provides tools for patients to easily access their genetic information.
-
2 Changes Siddhartha Mukherjee Is Calling for in Cancer Care
If the medical field wants to make serious progress on the Cancer Moonshot effort, it must expand its definition of personalized medicine and explore fresh approaches to cancer prevention, according to Dr. Siddhartha Mukherjee, a Pulitzer Prize-winning author and cancer physician at Columbia University Medical Center.
-
Where GE Healthcare stands 2 months away from spinning out
GE Healthcare is preparing for its spinoff from GE, which is planned for the first week of January. The company’s split will allow it to operate under a new board, as well as manage its own capital. That capital will be primarily invested in acquisitions and research and development efforts, according to GE Healthcare’s CEO for the U.S. and Canada.
-
MedCity Influencers, BioPharma
Reimagining healthcare in a quantum era
With promises of more efficient and reliable diagnoses, future breakthroughs in personalized medicine and targeted therapeutics, and an expedited R&D lifecycle, industry leaders must be prepared to invest in quantum technologies to deliver better outcomes for their organizations and patients.
-
A look ahead: How medical affairs may evolve over the next five years
Covid changed things for medical affairs teams at pharmaceutical companies, causing was a fundamental shift in the way they worked and functioned. The role of the medical science liaison—a key member of the medical affairs team—has also evolved.
-
Meditech’s genomic solution, which provides a patient’s full genetic history in their EHR, is now live
Clinton, Missouri-based Golden Valley Memorial Healthcare is the first to deploy Meditech’s solution, Expanse Genomics. It allows providers to analyze and parse genetic results into actionable data that is displayed directly in patient charts, according to Meditech.